The main risk factor for the development of cervical lesions is human papillomavirus (HPV) infection. Vaccination against human papillomavirus, which is offered to all girls aged 11 to 14, and catching up to girls aged 15 to 19, is an effective method of preventing cervical pathology. Despite this, human papillomavirus vaccination coverage remains low in France. Some women with cystic fibrosis might need a transplantation, which is a factor associated with increased risk of human papillomavirus carriage and cervical pathology. An over-risk of cervical pathology would also be present in non-transplanted women with cystic fibrosis. Particular attention should therefore be paid to vaccination in this population. The objective is to estimate the frequency of human papillomavirus vaccination in young patients with cystic fibrosis, and to evaluate the reasons for non-vaccination.
Study Type
OBSERVATIONAL
Enrollment
74
Informations are gathered through a self-report written questionnaire, completed by the patients or their parents.
Nouvel Hôpital d'Estaing CRCM Mixte
Clermont-Ferrand, France
CHU Grenoble
Grenoble, France
Cystic Fibrosis Reference Center, Hospices Civils de Lyon
Pierre-Bénite, France
Realization of human papillomavirus vaccination
The main outcome is the prevalence of human papillomavirus vaccination in young women with Cystic fibrosis. This data is collected using a questionnaire : HPV vaccination performed : yes/no
Time frame: 15 minutes
Type of vaccine used
This data is collected using a questionnaire : bivalent (Cervarix®) or quadrivalent (Gardasil®)
Time frame: 15 minutes
Respect for the vaccinal plan
This data is collected using a questionnaire : number and dates of injections
Time frame: 15 minutes
Reasons for non-vaccination
In case of non-vaccination reasons are collected using a multiple choices questionnaire
Time frame: 15 minutes
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.